Price$8.68+4.94 (+132.26%)
2026-03-112026-06-12
News · 26 weeks46+150%
2025-12-142026-06-07
Mix1890d
- Insider10(56%)
- Other4(22%)
- SEC Filings4(22%)
Latest news
25 items- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantumTEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the closing of its acquisition of approximately 54% interest in CliniQuantum Ltd. ("CliniQuantum"). According to the share purchase agreement (the "SPA"), pursuant to which, NeuroThera acquired 56,375 ordinary shares of CliniQuatum (the "Transaction"), representing approximately 54% of the issued and outstanding ordinary shares of CliniQuantum, in consideration for the issuance of 56,600,0
- INSIDERDirector Shrem Itschak sold $4,620 worth of Ordinary Shares (462 units at $10.00), decreasing direct ownership by 4% to 10,596 units (SEC Form 4)4 - SciSparc Ltd. (0001611746) (Issuer)
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantumTEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, received a conditional regulatory approval from the TSX Venture Exchange ("TSX") for the acquisition of approximately 54% interest in CliniQuantum Ltd. ("CliniQuantum") (the Transaction"). As previously disclosed, in March 2026, NeuroThera, CliniQuantum and the certain shareholders of CliniQuantum, (the "Selling Shareholders") entered into a share purchase agreement (the "SPA"), pursuant to which, N
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- SECSEC Form 20-F filed by SciSparc Ltd.20-F - SciSparc Ltd. (0001611746) (Filer)
- INSIDERSEC Form 3 filed by new insider Dayan Alon3 - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zuloff-Shani Adi3 - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERSEC Form 3 filed by new insider Vider Lior3 - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERSEC Form 3 filed by new insider Adler Oz3 - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERSEC Form 3 filed by new insider Shrem Itschak3 - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sidi Liat3 - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERSEC Form 3 filed by new insider Revach Moshe3 - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERSEC Form 3 filed by new insider Shay Amnon Ben3 - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERSEC Form 3 filed by new insider Weiss Amitay3 - SciSparc Ltd. (0001611746) (Issuer)
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression TherapyTEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has reported that pursuant to NeuroThera's ongoing collaboration with Clearmind Medicine Inc. ("Clearmind"), a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD). This innovative
- PRClearmind Medicine Announces Hong Kong Patent Filing for Depression TherapyInnovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030 Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver DiseaseTEL AVIV, Israel, March 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine Inc. with the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disea
- PRSciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trailsTEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a definitive share purchase agreement (the "SPA"), between NeuroThera, CliniQuantum Ltd. ("CliniQ") and the Selling Shareholders (as defined below) to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQ (the "CliniQ Shares") on a fully diluted basis immediately prior to the closing
- PRClearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver DiseaseInnovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed $200 billion by 2035 Vancouver, Canada, March 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT)
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc Announces 1-for-9 Reverse Share SplitFollowing the reverse share split, the Company will have approximately 565,000 outstanding shares, out of which approximately 561,533 will be publicly held Tel Aviv, Israel, March 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. ("SciSparc" or the "Company") (NASDAQ:SPRC), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today that it intends to effect a one-for-nine (1-for-9) reverse share split (the "Reverse Share Split") of the Company's issued and outstanding ordinary shares, no par value per share (the "Ordinary Shares"), effective at the market open on March 4, 2026. The Ordinary Shares will continue to t
SPRC FAQ
5 questionsWhat does SciSparc Ltd. do?
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health...Where does SPRC stock trade?
SciSparc Ltd. (SPRC) is listed on NASDAQ.What sector and industry is SPRC in?
SciSparc Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to SPRC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SPRC side-by-side with any of them on Quantisnow.How can I track SPRC on Quantisnow?
Quantisnow aggregates SciSparc Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SPRC to receive live email and push alerts on every new disclosure.